SILICON LABORATORIES INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SILICON LABORATORIES INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $491.63M | Feb 15, 2012 |
| FY2011 | Jan 1, 2011 | $493.34M | Feb 15, 2012 |
| FY2011 | Jan 2, 2010 | $441.02M | Feb 15, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $784.76M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $584.39M | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | $782.26M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $1.02B | Feb 4, 2025 |
| FY2023 | Jan 1, 2022 | $720.86M | Feb 20, 2024 |
| FY2022 | Jan 2, 2021 | $510.93M | Feb 1, 2023 |
| FY2021 | Dec 28, 2019 | $473.79M | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | $868.27M | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | $768.87M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $697.63M | Jan 30, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $768.87M | Jan 31, 2018 |
| FY2017 | Dec 31, 2016 | $697.63M | Jan 31, 2018 |
| FY2017 | Jan 2, 2016 | $644.83M | Jan 31, 2018 |
| FY2016 | Jan 3, 2015 | $620.70M | Feb 1, 2017 |
| FY2015 | Dec 28, 2013 | $580.09M | Feb 5, 2016 |
| FY2014 | Dec 29, 2012 | $563.29M | Feb 6, 2015 |
| FY2013 | Dec 31, 2011 | $491.63M | Jan 31, 2014 |
| FY2012 | Jan 1, 2011 | $493.34M | Feb 1, 2013 |
| FY2011 | Jan 2, 2010 | $441.02M | Feb 15, 2012 |
| FY2010 | Jan 3, 2009 | $415.63M | Feb 10, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $456.98M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $312.19M | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | $460.59M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $642.56M | Feb 4, 2025 |
| FY2023 | Jan 1, 2022 | $425.39M | Feb 20, 2024 |
| FY2022 | Jan 2, 2021 | $294.85M | Feb 1, 2023 |
| FY2021 | Dec 28, 2019 | $280.21M | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | $521.40M | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | $454.19M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $421.50M | Jan 30, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | ($64.91M) | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | ($191.01M) | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | ($34.52M) | Feb 10, 2026 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | ($70.54M) | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | ($165.49M) | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | ($24.15M) | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $119.26M | Feb 4, 2025 |
| FY2023 | Jan 1, 2022 | ($32.84M) | Feb 20, 2024 |
| FY2022 | Jan 2, 2021 | ($107.09M) | Feb 1, 2023 |
| FY2021 | Dec 28, 2019 | ($88.64M) | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | $85.21M | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | $84.97M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $66.28M | Jan 30, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $353.25M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $332.23M | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | $337.74M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $332.33M | Feb 4, 2025 |
| FY2023 | Jan 1, 2022 | $273.21M | Feb 20, 2024 |
| FY2022 | Jan 2, 2021 | $235.19M | Feb 1, 2023 |
| FY2021 | Dec 28, 2019 | $205.69M | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | $238.35M | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | $209.49M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $199.74M | Jan 30, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $174.28M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $145.45M | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | $147.00M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $190.97M | Feb 4, 2025 |
| FY2023 | Jan 1, 2022 | $185.02M | Feb 20, 2024 |
| FY2022 | Jan 2, 2021 | $166.75M | Feb 1, 2023 |
| FY2021 | Dec 28, 2019 | $163.17M | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | $197.84M | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | $159.73M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $155.48M | Jan 30, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $95.71M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | ($13.91M) | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | ($30.35M) | Feb 10, 2026 |
| FY2020 | Jan 2, 2021 | $135.72M | Feb 3, 2021 |
| FY2020 | Dec 28, 2019 | $166.52M | Feb 3, 2021 |
| FY2020 | Dec 29, 2018 | $173.54M | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | $189.52M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $128.91M | Jan 30, 2019 |
| FY2017 | Jan 2, 2016 | $105.45M | Jan 31, 2018 |
| FY2010 | Jan 1, 2011 | $117.94M | Feb 10, 2011 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $29.92M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $11.75M | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | $22.28M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $26.53M | Feb 4, 2025 |
| FY2023 | Jan 1, 2022 | $28.58M | Feb 20, 2024 |
| FY2022 | Jan 2, 2021 | $18.09M | Feb 1, 2023 |
| FY2021 | Dec 28, 2019 | $15.30M | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | $24.46M | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | $12.25M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $10.93M | Jan 30, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.27B | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $1.22B | Feb 10, 2026 |
| FY2024 | Dec 30, 2023 | $1.44B | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $2.17B | Feb 20, 2024 |
| FY2022 | Jan 1, 2022 | $2.96B | Feb 1, 2023 |
| FY2021 | Jan 2, 2021 | $1.99B | Feb 2, 2022 |
| FY2020 | Dec 28, 2019 | $1.67B | Feb 3, 2021 |
| FY2019 | Dec 29, 2018 | $1.62B | Jan 29, 2020 |
| FY2018 | Dec 30, 2017 | $1.54B | Jan 30, 2019 |
| FY2017 | Dec 31, 2016 | $1.08B | Jan 31, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $174.90M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $142.65M | Feb 10, 2026 |
| FY2024 | Dec 30, 2023 | $234.37M | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $764.42M | Feb 20, 2024 |
| FY2022 | Jan 1, 2022 | $745.87M | Feb 1, 2023 |
| FY2021 | Jan 2, 2021 | $793.65M | Feb 2, 2022 |
| FY2020 | Dec 28, 2019 | $559.80M | Feb 3, 2021 |
| FY2019 | Dec 29, 2018 | $557.06M | Jan 29, 2020 |
| FY2018 | Dec 30, 2017 | $582.07M | Jan 30, 2019 |
| FY2017 | Dec 31, 2016 | $254.89M | Jan 31, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.09B | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $1.08B | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | $1.21B | Feb 10, 2026 |
| FY2025 | Dec 31, 2022 | $1.41B | Feb 10, 2026 |
| FY2024 | Jan 1, 2022 | $2.21B | Feb 4, 2025 |
| FY2023 | Jan 2, 2021 | $1.20B | Feb 20, 2024 |
| FY2022 | Dec 28, 2019 | $1.12B | Feb 1, 2023 |
| FY2021 | Dec 29, 2018 | $1.07B | Feb 2, 2022 |
| FY2020 | Dec 30, 2017 | $953.02M | Feb 3, 2021 |
| FY2019 | Dec 31, 2016 | $826.96M | Jan 29, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $376.39M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $376.39M | Feb 10, 2026 |
| FY2024 | Dec 30, 2023 | $376.39M | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $376.39M | Feb 20, 2024 |
| FY2022 | Jan 1, 2022 | $376.39M | Feb 1, 2023 |
| FY2021 | Jan 2, 2021 | $376.39M | Feb 2, 2022 |
| FY2021 | Dec 28, 2019 | $237.29M | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | $397.34M | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | $288.23M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $276.13M | Jan 30, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $936.81M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $1.00B | Feb 10, 2026 |
| FY2024 | Dec 30, 2023 | $1.19B | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $1.42B | Feb 20, 2024 |
| FY2022 | Jan 1, 2022 | $2.21B | Feb 1, 2023 |
| FY2021 | Jan 2, 2021 | $993.66M | Feb 2, 2022 |
| FY2020 | Dec 28, 2019 | $980.61M | Feb 3, 2021 |
| FY2019 | Dec 29, 2018 | $961.34M | Jan 29, 2020 |
| FY2018 | Dec 30, 2017 | $851.31M | Jan 30, 2019 |
| FY2017 | Dec 31, 2016 | $802.00M | Jan 31, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $364.22M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | $281.61M | Feb 10, 2026 |
| FY2024 | Dec 30, 2023 | $227.50M | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $499.92M | Feb 20, 2024 |
| FY2022 | Jan 1, 2022 | $1.07B | Feb 1, 2023 |
| FY2021 | Jan 2, 2021 | $202.72M | Feb 2, 2022 |
| FY2020 | Dec 28, 2019 | $227.15M | Feb 3, 2021 |
| FY2019 | Dec 29, 2018 | $197.04M | Jan 29, 2020 |
| FY2018 | Dec 30, 2017 | $269.37M | Jan 30, 2019 |
| FY2017 | Dec 31, 2016 | $141.11M | Jan 31, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | (1) | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | (5) | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | (1) | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 4, 2025 |
| FY2023 | Jan 1, 2022 | 49 | Feb 20, 2024 |
| FY2022 | Jan 2, 2021 | 0 | Feb 1, 2023 |
| FY2021 | Dec 28, 2019 | 0 | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | 1 | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | 1 | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Jan 30, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | (1) | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | (5) | Feb 10, 2026 |
| FY2025 | Dec 30, 2023 | (1) | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 4, 2025 |
| FY2023 | Jan 1, 2022 | 47 | Feb 20, 2024 |
| FY2022 | Jan 2, 2021 | 0 | Feb 1, 2023 |
| FY2021 | Dec 28, 2019 | 0 | Feb 2, 2022 |
| FY2020 | Dec 29, 2018 | 1 | Feb 3, 2021 |
| FY2019 | Dec 30, 2017 | 1 | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Jan 30, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 32.96M | Feb 10, 2026 |
| FY2025 | Dec 28, 2024 | 32.46M | Feb 10, 2026 |
| FY2024 | Dec 30, 2023 | 31.90M | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | 31.99M | Feb 20, 2024 |
| FY2022 | Jan 1, 2022 | 38.48M | Feb 1, 2023 |
| FY2021 | Jan 2, 2021 | 43.93M | Feb 2, 2022 |
| FY2020 | Dec 28, 2019 | 43.50M | Feb 3, 2021 |
| FY2019 | Dec 29, 2018 | 43.09M | Jan 29, 2020 |
| FY2018 | Dec 30, 2017 | 42.71M | Jan 30, 2019 |
| FY2017 | Dec 31, 2016 | 41.89M | Jan 31, 2018 |